INFREQUENTLY METHYLATED EVENT AT SITES −181 TO −9 WITHIN THE 5′ CpG ISLAND OF E-CADHERIN IN NON-SMALL CELL LUNG CANCER

REFERENCES

• Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619–627
   PubMed Web of Science ®Google Scholar
• Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451–1455
   PubMed Web of Science ®Google Scholar
• Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M, Mori T. Expression of E–cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993; 53: 1696–1701
   PubMed Web of Science ®Google Scholar
• Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E–cadherin and beta–catenin in human non–small cell lung cancer and the clinical significance. Clin Cancer Res 2000; 6: 4789–4796
   PubMed Web of Science ®Google Scholar
• Hirata T, Fukuse T, Naiki H, Wada H. Expression of E–cadherin and lymph node metastasis in resected non–small–cell lung cancer. Clin Lung Cancer 2001; 3: 134–140
   PubMedGoogle Scholar
• Sulzer M A, Leers M P, van Noord J A, Bollen E C, Theunissen P H. Reduced E–cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non–small cell lung cancer. Am J Respir Crit Care Med 1998; 157: 1319–1323
   PubMed Web of Science ®Google Scholar
• Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H. E–cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer. Ann Thorac Surg 2001; 71: 949–954, discussion 954–945
   PubMed Web of Science ®Google Scholar
• Shibanuma H, Hirano T, Tsuji K, Wu Q, Shrestha B, Konaka C, Ebihara Y, Kato H. Influence of E–cadherin dysfunction upon local invasion and metastasis in non–small cell lung cancer. Lung Cancer 1998; 22: 85–95
   PubMed Web of Science ®Google Scholar
• Fei Q, Zhang H, Chen X, Wang J C, Zhang R, Xu W, Zhang Z, Zou W, Zhang K, Qi Q, Wang M, Tao S, Luo Z. Defected expression of E–cadherin in non–small cell lung cancer. Lung Cancer 2002; 37: 147–152
   PubMed Web of Science ®Google Scholar
• Chen X F, Zhang H T, Qi Q Y, Sun M M, Tao L Y. Expression of E–cadherin and nm23 is associated with the clinicopathological factors of human non–small cell lung cancer in China. Lung Cancer 2005; 48: 69–76
   PubMed Web of Science ®Google Scholar
• Hirohashi S. Inactivation of the E–cadherin–mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333–339
   PubMed Web of Science ®Google Scholar
• Nakayama S, Sasaki A, Mese H, Alcalde R E, Tsuji T, Matsumura T. The E–cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer 2001; 93: 667–673
   PubMed Web of Science ®Google Scholar
• Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E–cadherin invasion–suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A 1995; 92: 7416–7419
   PubMed Web of Science ®Google Scholar
• Esteller M. The coming of age of DNA methylation in medicine in the genomics and postgenomics era. Clin Immunol 2002; 103: 213–216
   PubMed Web of Science ®Google Scholar
• Toyooka S, Toyooka K O, Maruyama R, Virmani A K, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna J D, Gazdar A F. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1: 61–67
   PubMed Web of Science ®Google Scholar
• Zochbauer–Muller S, Fong K M, Virmani A K, Geradts J, Gazdar A F, Minna J D. Aberrant promoter methylation of multiple genes in non–small cell lung cancers. Cancer Res 2001; 61: 249–255
   PubMed Web of Science ®Google Scholar
• Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar A F. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004; 100: 1472–1477
   PubMed Web of Science ®Google Scholar
• Mountain C F. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710–1717
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu Z, Li W, Liu X, Chen X F, Zhang H T. Infrequently methylated event at sites -362 to -142 in the promoter of TGF beta R1 gene in non–small cell lung cancer. J Cancer Res Clin Oncol 2008; 134: 919–925
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao J, Chen X F, Li W, Liu R, Lei Z, Liu X, Peng X, Xu K, Chen J, Liu H, Zhou Q H, Zhang H T. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non–small cell lung cancer. Lung Cancer 2008; 62: 15–22
   PubMed Web of Science ®Google Scholar
• Corn P G, Heath E I, Heitmiller R, Fogt F, Forastiere A A, Herman J G, Wu T T. Frequent hypermethylation of the 5′ CpG island of E–cadherin in esophageal adenocarcinoma. Clin Cancer Res 2001; 7: 2765–2769
   PubMed Web of Science ®Google Scholar
• Zhang H T, Chen X F, Wang M H, Wang J C, Qi Q Y, Zhang R M, Xu W Q, Fei Q Y, Wang F, Cheng Q Q, Chen F, Zhu C S, Tao S H, Luo Z. Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non–small cell lung cancer. Clin Cancer Res 2004; 10: 2359–2367
   PubMed Web of Science ®Google Scholar
• Livak K J, Schmittgen T D. Analysis of relative gene expression data using real–time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–408
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun M J. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–130
   PubMed Web of Science ®Google Scholar
• Graff J R, Greenberg V E, Herman J G, Westra W H, Boghaert E R, Ain K B, Saji M, Zeiger M A, Zimmer S G, Baylin S B. Distinct patterns of E–cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res 1998; 58: 2063–2066
   PubMed Web of Science ®Google Scholar
• Tamura G, Yin J, Wang S, Fleisher A S, Zou T, Abraham J M, Kong D, Smolinski K N, Wilson K T, James S P, Silverberg S G, Nishizuka S, Terashima M, Motoyama T, Meltzer S J. E–Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569–573
   PubMed Web of Science ®Google Scholar
• Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D, Gray J. Mechanisms of inactivation of E–cadherin in breast cancer cell lines. Cancer Res 1998; 58: 1972–1977
   PubMed Web of Science ®Google Scholar
• Tsao S W, Liu Y, Wang X, Yuen P W, Leung S Y, Yuen S T, Pan J, Nicholls J M, Cheung A L, Wong Y C. The association of E–cadherin expression and the methylation status of the E–cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer 2003; 39: 524–531
   PubMed Web of Science ®Google Scholar
• Corn P G, Smith B D, Ruckdeschel E S, Douglas D, Baylin S B, Herman J G. E–cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 2000; 6: 4243–4248
   PubMed Web of Science ®Google Scholar
• Wang G, Hu X, Lu C, Su C, Luo S, Luo Z W. Promoter–hypermethylation associated defective expression of E–cadherin in primary non–small cell lung cancer. Lung Cancer 2008; 62: 162–172
   PubMed Web of Science ®Google Scholar
• Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E–cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 2008; 99: 738–746
   PubMed Web of Science ®Google Scholar
• Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 2006; 106: 2190–2199
   PubMed Web of Science ®Google Scholar
• Russo A L, Thiagalingam A, Pan H, Califano J, Cheng K H, Ponte J F, Chinnappan D, Nemani P, Sidransky D, Thiagalingam S. Differential DNA hypermethylation of critical genes mediates the stage–specific tobacco smoke–induced neoplastic progression of lung cancer. Clin Cancer Res 2005; 11: 2466–2470
   PubMed Web of Science ®Google Scholar